The third generation of TPO mimetics are again biologics
- Category: Press Room
- Published on Tuesday, 12 August 2008 11:53
- Hits: 9006
After failure of 1st generation thrombopoietic growth factors due to immunogencity, the 2nd generation is focused on oral TPO mimetics, now followed by a 3rd generation of engineered biologics with potential for higher potency and efficacy
Barcelona, Spain | August 12, 2008 | The Business Intelligence firm La Merie S.L. reported in its most recent pipeline update of thrombopoiesis stimulating agents that eight thrombopoietin (TPO) mimetics are in clinical stages of development. The two most advanced are close to FDA’s decision on the marketing application. Due to immunogenicity problems, TPO and pegylated TPO developments were abandoned, except one product approved in China. Second generation molecules reduced the immunogenicity problem by genetic engineering and by discovery of small molecule thrombopoietin receptor agonists with the additional advantage of oral drug delivery. At least five oral TPO agonists are in clinical development and one further compound is soon to follow. A third generation of thrombopoiesis stimulating agents consists of biologics generated by genetic engineering of existing growth factors, fusion of known and new growth factors or antibodies directed against new targets on megakaryocytes. Although most of the 3rd generation molecules are still in preclinical R&D, first data indicate the potential for higher potency. These results and more were found in a search conducted by La Merie Business Intelligence. The evaluation can be acquired at La Merie’s online store (www.pipelinereview.com/store ).
The report provides information on competitor projects in development as novel thrombopoiesis stimulating agents for treatment of idiopathic thrombocytopenic purpura (ITP) or prevention of severe thrombocytopenia and reduction of the need for platelet transfusion in patients undergoing chemotherapy. Two products are approved for treatment or prevention of thrombocytopenia.
About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.
PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on Research and Development in the Biopharmaceutical Industry. Visitors of PipelineReview.com will find R&D relevant press releases and can receive selected R&D news from one or more of the site’s News Channels. La Merie Daily and La Merie Biologics conveniently bring via e-mail a daily or weekly selection of the most interesting news from biopharmaceutical R&D. For more information visit www.pipelinereview.com.